• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267585 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
9 U, {& B' ]4 T' x, x* INOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 , E0 i9 R3 i  j
+ Author Affiliations/ c. y. H+ j, y- ?
# X: L; G! O. S- Q. Q0 q: f! X6 R
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 7 ~1 }+ X  D, v6 R  E3 I
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( [7 ]7 ^- Y, e1 M7 ^# n0 e9 [) o3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan , a: e$ G6 i: l0 T/ u/ t& F2 r
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
/ ]1 f" W) X  j  e! |5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan : p: I! r- O/ e
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 8 G( U* Q- M" B- w: a
7Kinki University School of Medicine, Osaka 589-8511, Japan
  M% t; u& V1 e8 W* T; Q' e  c3 n8Izumi Municipal Hospital, Osaka 594-0071, Japan
( r  E1 U9 s- Z' V) ^9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 8 J* ]4 s& ?' a5 E9 G0 w% ^
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
) A) K1 Y- X2 u4 R+ R, kAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
2 S+ i# P7 u4 `2 Z/ T* n5 n6 J& E4 H! t! c! f$ Q
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
$ q% E5 @/ y4 o+ b8 D) ]* `6 q3 ?4 M& ]: B3 Z6 _
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
4 v- a! m+ q; b- j6 Q2 F7 Q/ R" v0 ?9 ]  {1 s0 X
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
2 m' ^' A2 Q6 x& G2 l& f5 d
- I, c% j% U4 M9 j, V& YPublished online on: Thursday, December 1, 2011 7 l  M, B2 M/ P$ j9 S' f

' Q4 D, v9 s9 M( \% ZDoi: 10.3892/ol.2011.507 ( w! f- z+ l: @2 r/ ]
0 x& }" {& f: t8 G& o1 C  H2 n
Pages: 405-410
. g) V3 y0 m- g4 G$ W# B/ J: x8 b: ?: Q1 ~1 u( ^
Abstract:
; ~5 Q) ]9 X# @( y; u/ `5 i$ PS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.( L; l  w0 C% f, E/ t
4 ?, Z" L; z8 I6 O
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population7 n$ y. E/ s' q' h+ e5 O
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 + I( }: t( W- P" A) ?: h# A
+ Author Affiliations! W5 }- t' U( `  }  G9 K
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu % u2 G0 _" b5 X
2Department of Thoracic Surgery, Kyoto University, Kyoto ' y1 A6 K0 Y% g4 e8 c1 W$ g
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
4 v: v! `8 e* E&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp ' o0 g  E; R( ?' n- {8 _/ L% O
Received September 3, 2010. ( W) n# ~) m% i
Revision received November 11, 2010. 4 \( V/ W" ^/ {/ C
Accepted November 17, 2010.
6 W; Y  @( N. d6 l! W' u8 C! B( XAbstract
* K- c6 e7 [" b) W8 q8 [5 sBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. + a0 M3 y1 l  J$ ]5 ~
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 5 A, ^% j8 {$ k
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
- a+ ?/ Q/ Z$ L; N2 MConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. $ Q" r3 m8 v1 g  z! L6 f, x
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
1 M$ r' w5 h  r# f( j今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?' Z0 O& S4 l9 X( @, A
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy' q# h6 o6 Y9 ~. v, c. q
http://clinicaltrials.gov/ct2/show/NCT01523587
  z; Y: k' z& `+ E! |9 y5 t  ]4 B6 i2 g4 Y
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC) V9 _+ l# y8 ~. C$ I
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 0 C/ B7 `5 p, v! P

9 v. B* ?! R) ^4 z( q从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: c" Z* h* ^7 x* H至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

; W- G2 n$ \! T. r% h没有副作用是第一追求,效果显著是第二追求。
( F3 d0 n7 T% F- o8 S. A( A" W7 {不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表